Search Results - "PÉREZ‐ANDREU, V."

Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome by TERUEL, R., PÉREZ‐SÁNCHEZ, C., CORRAL, J., HERRANZ, M. T., PÉREZ‐ANDREU, V., SAIZ, E., GARCÍA‐BARBERÁ, N., MARTÍNEZ‐MARTÍNEZ, I., ROLDÁN, V., VICENTE, V., LÓPEZ‐PEDRERA, C., MARTÍNEZ, C.

“…Background: Tissue factor (TF) is the main initiator of the coagulation cascade and elements that may upregulate its expression might provoke thrombotic…”
Get full text

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements by PÉREZ‐ANDREU, V., ROLDÁN, V., LÓPEZ‐FERNÁNDEZ, M. F., ANTÓN, A. I., ALBERCA, I., CORRAL, J., MONTES, R., GARCÍA‐BARBERÁ, N., FERRANDO, F., VICENTE, V., GONZÁLEZ‐CONEJERO, R.

“…Background: There is currently intense debate as to whether pharmacogenetic algorithms for estimating the initial dose of coumarins provide a more accurate…”
Get full text

Creating a genotype-based dosing algorithm for acenocoumarol steady dose by Cerezo-Manchado, Juan J, Rosafalco, Mario, Antón, Ana I, Pérez-Andreu, Virginia, Garcia-Barberá, Nuria, Martinez, Ana B, Corral, Javier, Vicente, Vincente, González-Conejero, Rocio, Roldán, Vanessa

“…Acenocoumarol is a commonly prescribed anticoagulant drug for the prophylaxis and treatment of venous and arterial thromboembolic disorders in several…”
Get more information

miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle by Pérez-Andreu, Virginia, Teruel, Raúl, Corral, Javier, Roldán, Vanessa, García-Barberá, Nuria, Salloum-Asfar, Salam, Gómez-Lechón, María José, Bourgeois, Stephane, Deloukas, Panos, Wadelius, Mia, Vicente, Vicente, González-Conejero, Rocío, Martínez, Constantino

“…Regulation of key proteins by microRNAs (miRNAs) is an emergent field in biomedicine. Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) is a relevant…”
Get full text

Response by Perez-Andreu, V., Xu, H., Yang, J. J.

Get full text

Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation by Ruiz-Nodar, Juan M., Marín, Francisco, Sánchez-Payá, José, Hurtado, José A., Valencia-Martín, José, Manzano-Fernández, Sergio, Roldán, Vanessa, Pérez-Andreu, Virginia, Sogorb, Francisco, Valdés, Mariano, Lip, Gregory Y.H.

“…Aims Drug-eluting stents (DES) have never been sufficiently studied in patients with atrial fibrillation (AF). The latter are considered as a high-risk…”
Get full text